A new study has found that anti-anxiety drugs and sleeping pills could increase risk of death.
The study from the University of Warwick shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with a doubling in the risk of mortality.
Although these findings are based on routine data and need to be interpreted cautiously, the researchers recommended that a greater understanding of their impact is essential.
"The key message here is that we really do have to use these drugs more carefully. This builds on a growing body of evidence suggesting that their side effects are significant and dangerous. We have to do everything possible to minimise over reliance on anxiolytics and sleeping pills," Professor Scott Weich, Professor of Psychiatry at the University of Warwick said.
"That's not to say that they cannot be effective. But particularly due to their addictive potential we need to make sure that we help patients to spend as little time on them as possible and that we consider other options, such as cognitive behavioural therapy, to help them to overcome anxiety or sleep problems," he added.
The study accounted, where possible, for other factors such as age, smoking and alcohol use, other prescriptions and socioeconomic status. Crucially, the team controlled for contributing risk factors such as sleep disorders, anxiety disorders and other psychiatric illness in all participants.
The study is published in BMJ.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
